Ausgabe 1/2016
Inhalt (59 Artikel)
Association between dental amalgam fillings and Alzheimer’s disease
Amin Zarghami, Seyyed Mohammad Masoud Hojjati
Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment
Sepideh Shokouhi, John W. Mckay, Suzanne L. Baker, Hakmook Kang, Aaron B. Brill, Harry E. Gwirtsman, William R. Riddle, Daniel O. Claassen, Baxter P. Rogers
A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimer’s disease
Monica H. Breitve, Minna J. Hynninen, Kolbjørn Brønnick, Luiza J. Chwiszczuk, Bjørn H. Auestad, Dag Aarsland, Arvid Rongve
Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease
Jeffrey L. Cummings, Kate Zhong, Jefferson W. Kinney, Chelcie Heaney, Joanne Moll-Tudla, Abhinay Joshi, Michael Pontecorvo, Michael Devous, Anne Tang, James Bena
An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer’s disease
Abdel G. Elkahloun, Roman Hafko, Juan M. Saavedra
Increased CSF tau level is correlated with decreased lamina cribrosa thickness
Eun Ji Lee, Tae-Woo Kim, Dae Seung Lee, Hyunjoong Kim, Young Ho Park, Jungeun Kim, Joon Woo Lee, SangYun Kim
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy
Carina Wattmo, Lennart Minthon, Åsa K. Wallin
Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies
Jana Podhorna, Tillmann Krahnke, Michael Shear, John E Harrison
Mini Mental State Examination and Logical Memory scores for entry into Alzheimer’s disease trials
Kimberly R. Chapman, Hanaan Bing-Canar, Michael L. Alosco, Eric G. Steinberg, Brett Martin, Christine Chaisson, Neil Kowall, Yorghos Tripodis, Robert A. Stern
Cognitive and affective theory of mind in dementia with Lewy bodies and Alzheimer’s disease
Camille Heitz, Vincent Noblet, Clélie Phillipps, Benjamin Cretin, Natacha Vogt, Nathalie Philippi, Jennifer Kemp, Xavier de Petigny, Mathias Bilger, Catherine Demuynck, Catherine Martin-Hunyadi, Jean-Paul Armspach, Frédéric Blanc
A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans
Mikko Hölttä, Robert A. Dean, Eric Siemers, Kwasi G. Mawuenyega, Wendy Sigurdson, Patrick C. May, David M. Holtzman, Erik Portelius, Henrik Zetterberg, Randall J. Bateman, Kaj Blennow, Johan Gobom
First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease
Marielle Delnomdedieu, Sridhar Duvvuri, David Jianjun Li, Nazem Atassi, Ming Lu, H. Robert Brashear, Enchi Liu, Seth Ness, James W. Kupiec
Transcranial direct current stimulation as a memory enhancer in patients with Alzheimer’s disease: a randomized, placebo-controlled trial
Martin Bystad, Ole Grønli, Ingrid Daae Rasmussen, Nina Gundersen, Lene Nordvang, Henrik Wang-Iversen, Per M. Aslaksen
Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
Veronika Logovinsky, Andrew Satlin, Robert Lai, Chad Swanson, June Kaplow, Gunilla Osswald, Hans Basun, Lars Lannfelt
CRTC1 gene is differentially methylated in the human hippocampus in Alzheimer’s disease
Maite Mendioroz, Naiara Celarain, Miren Altuna, Javier Sánchez-Ruiz de Gordoa, María Victoria Zelaya, Miren Roldán, Idoya Rubio, Rosa Larumbe, María Elena Erro, Iván Méndez, Carmen Echávarri
Classification of the primary progressive aphasias: principles and review of progress since 2011
Rik Vandenberghe
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Kristi Henjum, Ina S. Almdahl, Vibeke Årskog, Lennart Minthon, Oskar Hansson, Tormod Fladby, Lars N. G. Nilsson
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Rik Vandenberghe, Juha O. Rinne, Mercè Boada, Sadao Katayama, Philip Scheltens, Bruno Vellas, Michael Tuchman, Achim Gass, Jochen B. Fiebach, Derek Hill, Kasia Lobello, David Li, Tom McRae, Prisca Lucas, Iona Evans, Kevin Booth, Gerald Luscan, Bradley T. Wyman, Lisa Hua, Lingfeng Yang, H. Robert Brashear, Ronald S. Black
The algorithm for Alzheimer risk assessment based on APOE promoter polymorphisms
Anna Limon-Sztencel, Beata S. Lipska-Ziętkiewicz, Magdalena Chmara, Bartosz Wasag, Leszek Bidzan, Beata R. Godlewska, Janusz Limon
miRNA-dependent target regulation: functional characterization of single-nucleotide polymorphisms identified in genome-wide association studies of Alzheimer’s disease
Charlotte Delay, Benjamin Grenier-Boley, Philippe Amouyel, Julie Dumont, Jean-Charles Lambert
Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors
Bianca Van Broeck, Maarten Timmers, Steven Ramael, Jennifer Bogert, Leslie M. Shaw, Marc Mercken, John Slemmon, Luc Van Nueten, Sebastiaan Engelborghs, Johannes Rolf Streffer
High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer’s disease
Malin Degerman Gunnarsson, Martin Ingelsson, Kaj Blennow, Hans Basun, Lars Lannfelt, Lena Kilander
Recent global trends in the prevalence and incidence of dementia, and survival with dementia
Martin Prince, Gemma-Claire Ali, Maëlenn Guerchet, A. Matthew Prina, Emiliano Albanese, Yu-Tzu Wu
Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies
Adrian Ivanoiu, Jérémie Pariente, Kevin Booth, Kasia Lobello, Gerald Luscan, Lisa Hua, Prisca Lucas, Scot Styren, Lingfeng Yang, David Li, Ronald S. Black, H. Robert Brashear, Thomas McRae
The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease
Hussein N. Yassine, Varun Rawat, Wendy J. Mack, Joseph F. Quinn, Karin Yurko-Mauro, Eileen Bailey-Hall, Paul S. Aisen, Helena C. Chui, Lon S. Schneider
Exploring anterograde memory: a volumetric MRI study in patients with mild cognitive impairment
N. Philippi, V. Noblet, E. Duron, B. Cretin, C. Boully, I. Wisniewski, M. L. Seux, C. Martin-Hunyadi, E. Chaussade, C. Demuynck, S. Kremer, S. Lehéricy, D. Gounot, J. P. Armspach, O. Hanon, F. Blanc
Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study
Claire Paquet, Eloi Magnin, David Wallon, Anne-Cécile Troussière, Julien Dumurgier, Alain Jager, Frank Bellivier, Elodie Bouaziz-Amar, Frédéric Blanc, Emilie Beaufils, Carole Miguet-Alfonsi, Muriel Quillard, Susanna Schraen, Florence Pasquier, Didier Hannequin, Philippe Robert, Jacques Hugon, François Mouton-Liger
Retraction Note: Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis
Lin Tan, Lan Tan, Hui-Fu Wang, Jun Wang, Chen-Chen Tan, Meng-Shan Tan, Xiang-Fei Meng, Chong Wang, Jin-Tai Yu
Brain perfusion in dementia with Lewy bodies and Alzheimer’s disease: an arterial spin labeling MRI study on prodromal and mild dementia stages
Daniel Roquet, Marion Sourty, Anne Botzung, Jean-Paul Armspach, Frédéric Blanc
Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery device
Helga Eyjolfsdottir, Maria Eriksdotter, Bengt Linderoth, Göran Lind, Bengt Juliusson, Philip Kusk, Ove Almkvist, Niels Andreasen, Kaj Blennow, Daniel Ferreira, Eric Westman, Inger Nennesmo, Azadeh Karami, Taher Darreh-Shori, Ahmadul Kadir, Agneta Nordberg, Erik Sundström, Lars-Olof Wahlund, Anders Wall, Maria Wiberg, Bengt Winblad, Åke Seiger, Lars Wahlberg, Per Almqvist
Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer’s disease
Frederic Blanc, Sean J. Colloby, Benjamin Cretin, Paulo Loureiro de Sousa, Catherine Demuynck, John T. O’Brien, Catherine Martin-Hunyadi, Ian McKeith, Nathalie Philippi, John-Paul Taylor
Older patients are still under-represented in clinical trials of Alzheimer’s disease
Rita Banzi, Paolo Camaioni, Mauro Tettamanti, Vittorio Bertele’, Ugo Lucca
A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline
Penny A. Dacks, Joshua J. Armstrong, Stephen K. Brannan, Aaron J. Carman, Allan M. Green, M. Sue Kirkman, Lawrence R. Krakoff, Lewis H. Kuller, Lenore J. Launer, Simon Lovestone, Elizabeth Merikle, Peter J. Neumann, Kenneth Rockwood, Diana W. Shineman, Richard G. Stefanacci, Priscilla Velentgas, Anand Viswanathan, Rachel A. Whitmer, Jeff D. Williamson, Howard M. Fillit
Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer’s disease
Jean-François Blain, Matthew G. Bursavich, Emily A. Freeman, Lori A. Hrdlicka, Hilliary E. Hodgdon, Ting Chen, Don E. Costa, Bryce A. Harrison, Sudarshan Kapadnis, Deirdre A. Murphy, Scott Nolan, Zhiming Tu, Cuyue Tang, Duane A. Burnett, Holger Patzke, Gerhard Koenig
Alzheimer’s Research UK 2016 Conference report
Rosa M. Sancho, Carla J. Cox, Laura E. Phipps, Simon H. Ridley
Generation of a new transgenic mouse model for assessment of tau gene silencing therapies
Susan Fromholt, Christian Reitano, Hilda Brown, Jada Lewis, David R. Borchelt
A proposed preventive role for Gamma-hydroxybutyrate (XyremR) in Alzheimer’s disease
Michel Maitre, Christian Klein, Ayikoe G. Mensah-Nyagan
Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease
Laure Saint-Aubert, Ove Almkvist, Konstantinos Chiotis, Rita Almeida, Anders Wall, Agneta Nordberg
Drug development in Alzheimer’s disease: the path to 2025
Jeffrey Cummings, Paul S. Aisen, Bruno DuBois, Lutz Frölich, Clifford R. Jack Jr, Roy W. Jones, John C. Morris, Joel Raskin, Sherie A. Dowsett, Philip Scheltens
Protective effect of melatonin on soluble Aβ1–42-induced memory impairment, astrogliosis, and synaptic dysfunction via the Musashi1/Notch1/Hes1 signaling pathway in the rat hippocampus
Shuman Zhang, Pan Wang, Lili Ren, Chunli Hu, Jing Bi
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
Annika Öhrfelt, Ann Brinkmalm, Julien Dumurgier, Gunnar Brinkmalm, Oskar Hansson, Henrik Zetterberg, Elodie Bouaziz-Amar, Jacques Hugon, Claire Paquet, Kaj Blennow
Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs
Stefanie Lerche, Kathrin Brockmann, Andrea Pilotto, Isabel Wurster, Ulrike Sünkel, Markus A. Hobert, Anna-Katharina von Thaler, Claudia Schulte, Erik Stoops, Hugo Vanderstichele, Victor Herbst, Britta Brix, Gerhard W. Eschweiler, Florian G. Metzger, Walter Maetzler, Daniela Berg
Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients
Rinko Grewal, Mona Haghighi, Shuai Huang, Amanda G. Smith, Chuanhai Cao, Xiaoyang Lin, Daniel C. Lee, Nancy Teten, Angela M. Hill, Maj-Linda B. Selenica
ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension
Laura M. Gault, Robert A. Lenz, Craig W. Ritchie, Andreas Meier, Ahmed A. Othman, Qi Tang, Scott Berry, Yili Pritchett, Weining Z. Robieson
Using the Affiliate Stigma Scale with caregivers of people with dementia: psychometric evaluation
Chih-Cheng Chang, Jian-An Su, Chung-Ying Lin
Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic review
S. A. S. A. Bemelmans, K. Tromp, E. M. Bunnik, R. J. Milne, S. Badger, C. Brayne, M. H. Schermer, E. Richard
Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study
Klaus Hager, Alan S. Baseman, Jeffrey S. Nye, H. Robert Brashear, John Han, Mary Sano, Bonnie Davis, Henry M. Richards
Outcomes measures in a decade of dementia and mild cognitive impairment trials
Jennifer Kirsty Harrison, Anna H. Noel-Storr, Nele Demeyere, Emma L. Reynish, Terry J. Quinn
Changes in cerebral glucose metabolism after 3 weeks of noninvasive electrical stimulation of mild cognitive impairment patients
Kyongsik Yun, In-Uk Song, Yong-An Chung
Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology
Patrick Gavin Kehoe, Steffenny Wong, Noura AL Mulhim, Laura Elyse Palmer, J. Scott Miners
Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
Panagiotis Alexopoulos, Lukas Werle, Jennifer Roesler, Nathalie Thierjung, Lena Sophie Gleixner, Igor Yakushev, Nikolaos Laskaris, Stefan Wagenpfeil, Philippos Gourzis, Alexander Kurz, Robert Perneczky
An update on semantic dementia: genetics, imaging, and pathology
Ramon Landin-Romero, Rachel Tan, John R. Hodges, Fiona Kumfor
SORL1 gene, plasma biomarkers, and the risk of Alzheimer’s disease for the Han Chinese population in Taiwan
Cheng-Ta Chou, Yi-Chu Liao, Wei-Ju Lee, Shuu-Jiun Wang, Jong-Ling Fuh
Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology
Nicole Maphis, Shanya Jiang, Guixiang Xu, Olga N. Kokiko-Cochran, Saktimayee M. Roy, Linda J. Van Eldik, D. Martin Watterson, Bruce T. Lamb, Kiran Bhaskar
Desire for predictive testing for Alzheimer’s disease and impact on advance care planning: a cross-sectional study
Meera Sheffrin, Irena Stijacic Cenzer, Michael A. Steinman
Brain activation in frontotemporal and Alzheimer’s dementia: a functional near-infrared spectroscopy study
Florian G. Metzger, Betti Schopp, Florian B. Haeussinger, Katja Dehnen, Matthis Synofzik, Andreas J. Fallgatter, Ann-Christine Ehlis
LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1ΔE9 transgenic mice
Jian-Hui Wang, Xi Lei, Xiao-Rui Cheng, Xiao-Rui Zhang, Gang Liu, Jun-Ping Cheng, Yi-Ran Xu, Ju Zeng, Wen-Xia Zhou, Yong-Xiang Zhang
A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1–42 peptide in human plasma with utility for studies of Alzheimer’s disease therapeutics
Linan Song, D. Richard Lachno, David Hanlon, Adam Shepro, Andreas Jeromin, Dipika Gemani, Jayne A. Talbot, Margaret M. Racke, Jeffrey L. Dage, Robert A. Dean
The societal costs of dementia in Sweden 2012 – relevance and methodological challenges in valuing informal care
Anders Wimo, Linus Jönsson, Laura Fratiglioni, Per Olof Sandman, Anders Gustavsson, Anders Sköldunger, Lennarth Johansson